{
    "clinical_study": {
        "@rank": "149678", 
        "acronym": "PICC-1", 
        "arm_group": {
            "arm_group_label": "Colon&Rectal Stage II /Stage III"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine association between Peripheral Immune Cells(PIC)\n      and recurrence in stage II/III colorectal cancer"
        }, 
        "brief_title": "Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer", 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators hypothesize differentiation of Peripheral Immune Cells(PIC) would result\n      in resistance of chemotherapy and tumor local of metastatic recurrence.\n\n      The primary endpoint of this study is Disease Free Survival and the secondary endpoint is\n      5-year Overall Survival.\n\n      5ml peripheral blood will be sorted and counted through flow cytometry at the point of\n      before primary treatment(surgery for colon cancers, neoadjuvant therapy for rectal cancers)\n      , before the first chemotherapy postoperatively and 1 month after last chemotherapy.\n\n      Patients will be followed up with 3 monthly assessments in the first two years and 6 monthly\n      assessments in the rest three years. Stratification factors include age , BMI , gender ,\n      tumor location , rectal or colon cancer stage,the  chemotherapy (FOLFOX, XELOX, DeGramont or\n      Capecitabine ),laparoscopic or laprotomy, anastomosis, concomitant medications and\n      complications."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinically /Pahohistologically diagnosed as stageII/III CRC\n\n          -  ECOG    0-2\n\n          -  Age      18-90\n\n          -  Gender    both\n\n        Exclusion Criteria:\n\n          -  Distant metastases noticed before or during surgery\n\n          -  History of malignant tumor disease\n\n          -  History of autoimmune diseases or immunodeficiencies\n\n          -  History of hematological disease\n\n          -  History of hepatic cirrhosis or Splenomegaly\n\n          -  History of chronic kidney disease\n\n          -  History of organ transplant\n\n          -  History of chronic inflammatory disease\n\n          -  Use of hematological drugs within 1 year prior to surgery\n\n          -  Use of immunodulatory drugs within 1 year prior to surgery\n\n          -  Use of chemotherapeutic drugs within 1 year prior to surgery\n\n          -  Long term Use of non-steroid anti-inflammatory drugs(>6 months)\n\n          -  Unable or Unwilling to undergo all the standard treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Stage II /Stage III Colorectal Patients"
            }
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911988", 
            "org_study_id": "XHGC 001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral immune cells", 
            "Colorectal Cancers", 
            "Stage II/ Stage III", 
            "Recurrence", 
            "Metastasis"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "contact": {
                "email": "longcuidr@126.com", 
                "last_name": "Long Cui, MD.PhD", 
                "phone": "+86-21-25077863"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "2000092"
                }, 
                "name": "Medical Center of Colon&Rectal Cancers"
            }, 
            "investigator": [
                {
                    "last_name": "Long Cui, MD.PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wei Shen, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer", 
        "overall_contact": {
            "email": "longcuidr@126.com", 
            "last_name": "Long Cui, MD.PhD", 
            "phone": "+86-21-25077863"
        }, 
        "overall_contact_backup": {
            "email": "joanshenwei@126.com", 
            "last_name": "Wei Shen, MD"
        }, 
        "overall_official": {
            "affiliation": "Medical Center of Colon&Rectal Cancers, Shanghai Xinhua Hospital affiliated to Shanghai Jiaotong University", 
            "last_name": "Long Cui, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The time from resection to the time of disease recurrence(local or metastatic) or death from any cause.", 
            "measure": "Disease Free Survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911988"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Xinhua Hospital", 
            "investigator_full_name": "Long Cui", 
            "investigator_title": "Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "the time from resection to the time of death from any cause", 
            "measure": "5 years overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 years or the time of death"
        }, 
        "source": "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}